Koninklijke Philips NV vs Western Alliance Bancorporation — how do they compare? Koninklijke Philips NV trades at $24.38 (market cap $23.52B), while Western Alliance Bancorporation trades at $76.21 (market cap $8.24B). The key difference: Koninklijke Philips NV is far larger — about 2.9× Western Alliance Bancorporation's market cap, and Koninklijke Philips NV pays the higher dividend (4.17%). Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Western Alliance Bancorporation for 3 Days on average.
| PHG | WAL | |
|---|---|---|
Market Cap | $23.52B | $8.24B |
Volume | 1,635,069 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $32.91 | $96.08 |
52-Week Low | $23.81 | $66.70 |
Typical Hold Time | 84 Days | 3 Days |
Enterprise Value | $29.87B | $9.76B |
Dividend Yield | 4.17% | 2.23% |
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% on the day, with a bearish technical outlook despite strong fundamentals. The company maintains robust profitability with 25.43% net income margin and 13.43% ROE, supported by recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX digital asset platform and participation in major financial conferences, while institutional investors show mixed positioning.
WAL presents a compelling value opportunity with attractive valuation multiples (P/E 8.39, P/B 1.07) and strong analyst support (79% buy ratings, $84.33 consensus target). However, near-term risks include the recent Q2 2026 EPS miss, bearish technical indicators, and regulatory uncertainty around Fed policy changes affecting bank asset thresholds.
Trailing returns across standard periods
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →